Oral Oncology
Volume 45, Issue 12 , Pages 1015-1020 , December 2009

Mucositis: The impact, biology and therapeutic opportunities of oral mucositis

Received 7 August 2009 ,Revised 25 August 2009 ,Accepted 25 August 2009.

References 

  1. Sonis ST. Is mucositis an inevitable consequence of intensive therapy for hematologic cancers?. Nat Clin Pract Oncol. 2005;2:134–135
  2. Spielberger R, et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. New Engl J Med. 2004;351:2590–2598
  3. Keefe DM. Mucositis guidelines: what have they achieved, and where to from here?. Support Care Cancer. 2006;14:489–491
  4. Elting LS, Keefe DM, Sonis ST, et al. Patient-reported measurements of oral mucositis in head and neck cancer patients treated with radiotherapy with or without chemotherapy: demonstration of increased frequency, severity, resistance to palliation, and impact on quality of life. Cancer. 2008;113:2704–2713
  5. Nonzee NJ, Dandade NA, Patel U, et al. Evaluating the supportive costs of severe radiochemotherapy-induced mucositis and pharyngitis: results from a Northwestern University Cost of Cancer Program pilot study with head and neck and nonsmall cell lung cancer patients who received care at a county hospital, a veterans administration hospital, or a comprehensive cancer center. Cancer. 2008;113:1446–1452
  6. Sonis ST, Oster G, Fuchs H, et al. Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol. 2001;19:2201–2205
  7. Grunberg S, Hesketh P, Randolph-Jackson P, et al. Risk, quality of life impact of mucosal injury among colorectal cancer patients receiving FOLFOX chemotherapy. Support Care Cancer. 2007;15:704
  8. Keefe DM, Sonis ST, Bowen JM. Emerging drugs for chemotherapy-induced mucositis. Expert Opin Emerg Drugs. 2008;13:511–522
  9. Gerullis H, Bergmann L, Mante L, et al. Experiences and practical conclusions concerning temsirolimus use and adverse event management in advanced renal cell carcinoma within a compassionate use program in Germany. Cancer Chemother Pharmacol. 2009;63:1097–1102
  10. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25:1960–1966
  11. Sonis ST. Mucositis as a biological process: a new hypothesis for the development of chemotherapy-induced stomatotoxicity. Oral Oncol. 1998;34:39–43
  12. Sonis ST. The pathobiology of mucositis. Nat Rev Cancer. 2004;4:277–284
  13. Logan RM, Stringer AM, Bowen JM, et al. Is the pathobiology of chemotherapy-induced alimentary tract mucositis influenced by the type of mucotoxic drug administered. Cancer Chemother Pharmacol. 2009;63:239–251
  14. Sonis ST. Pathobiology of oral mucositis: novel insights and opportunities. J Support Oncol. 2007;5:3–11
  15. Sonis ST, Haddad R, Posner M, et al. Gene expression changes in peripheral blood cells provide insight into the biological mechanisms associated with regimen-related toxicities in patients being treated for head and neck cancers. Oral Oncol. 2007;43:289–300
  16. Logan RM, Stringer AM, Bowen JM, et al. Serum levels of NF-κB and proinflammatory cytokines following administration of mucotoxic drugs. Cancer Biol Ther. 2008;7:1139–1145
  17. Logan RM, Gibson RJ, Sonis ST, et al. Nuclear factor-κB (NF-κB) and cyclooxygenase-2 (COX-2) expression in the oral mucosa following cancer chemotherapy. Oral Oncol. 2007;43:395–401
  18. Sonis ST. The biologic role for nuclear factor-κB in disease and its potential involvement in mucosal injury associated with anti-neoplastic therapy. Crit Rev Oral Biol Med. 2002;13:380–389
  19. Hwang D, Popat R, Bragdon C, et al. Effects of ceramide inhibition on experimental radiation-induced mucositis. Oral Surg, Oral Med, Oral Pathol, Oral Radiol Endod. 2005;100:321–329
  20. Al-Dasooqi N, Gibson RJ, Bowen JM, et al. Matrix metalloproteinases: key regulators in the pathogenesis of chemotherapy-induced mucositis. Cancer Chemother Pharmacol. 2009;64:1–9
  21. Uzel NG, Socransky S, Hwang D. The potential of periodontal pathogens in the development of experimental radiation-induced mucositis. Personal communication.
  22. Tran KT, Griffith L, Wells A. Extracellular matrix signaling through growth factor receptors during wound healing. Wound Rep Reg. 2004;12:262–268
  23. Basson MD. In vitro evidence for matrix regulation of intestinal epithelial biology during mucosal healing. Life Sci. 2001;69:3005–3018
  24. Barasch A, Peterson DE. Risk factors for ulcerative oral mucositis in cancer patients: unanswered questions. Oral Oncol. 2003;39:91–100
  25. Chansky K, Benedetti J, Macdonald JS. Differences in toxicity between men and women treated with 5-fluorouracil therapy for colorectal carcinoma. Cancer. 2005;103:1165–1171
  26. Chen E. Impact of pre-existing psoriasis and Addison’s disease on chemotherapy-induced mucositis in patients with hematological maliganancies. Pre-doctoral thesis, Harvard School of Dental Medicine; 2004.
  27. Schwab M, Zanger UM, Marx C, et al. Role of genetic and nongenetic factors for flurouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU toxicity study group. J Clin Oncol. 2008;26:2131–2138
  28. Bogunia-Kubik K, Polak M, Lange A. TNF polymorphisms are associated with toxic but not with aGVHD complications in the recipients of allogeneic sibling haematopoietic stem cell transplantation. Bone Marrow Transplant. 2003;32:617–622
  29. Ambrosone CB, Tian C, Ahn J, et al. Genetic predictors of acute toxicities related to radiation therapy following lumpectomy for breast cancer: a case-series study. Breast Cancer Res. 2006;8:R40
  30. Ostman A, Augstem M. Cancer-associated fibroblasts and tumor growth–bystanders turning into key players. Curr Opin Genet Dev. 2009;19:67–73
  31. Pries R, Wollenberg B. Cytokines in head and neck cancer. Cytokine Growth Factor Rev. 2006;17:141–146
  32. Bose A, Chakraborty T, Chakraborty K, et al. Dysregulation in immune functions by peripheral blood mononuclear cells from head, neck squamous cell carcinoma patients. Cancer Immunol. 2008;8:10
  33. Body GP, Rodriguize CV, Chang NY, et al. Fever and infection in leukemic patients: a study of 464 consecutive patients. Cancer. 1978;41:1610–1622
  34. Donnelly JP, Bellm LA, Epstein JB, et al. Antimicrobial therapy to prevent or treat oral mucositis. Lancet Infect Dis. 2003;3:405–412
  35. Scarantino C. LeVeque , Swann RS, et al. Effect of pilocarpine during radiation therapy: results of RTOG 97–09, a phase III, randomized study in head and neck cancer patients. J Support Oncol. 2006;4:252–258
  36. Lockhart PB, Brennan MT, Kent ML, et al. Randomized controlled trial of pilocarpine hydrochloride for the moderation of oral mucositis during autologous blood stem cell transplantation. Bone Marrow Transplant. 2005;35:713–720
  37. El-Sayed S, Nabid A, Shelley W, et al. Prophylaxis of radiation-associated mucositis in conventionally treated patients with head and neck cancer: a double-blind, phase III, randomized, controlled trial evaluating the clinical efficacy of an antimicrobial lozenge using a validated mucositis scoring system. J Clin Oncol. 2002;20:3956–3963
  38. Rand KH, Kramer B, Johnson AC. Cancer chemotherapy associated symptomatic stomatitis: role of Herpes simplex virus (HSV). Cancer. 1982;50:1262–1265
  39. Woo SB, Sonis ST, Sonis AL. The role of herpes simplex virus in the development of oral mucositis in bone marrow transplant patients. Cancer. 1990;66:2375–2379
  40. Djuric M, Jankovic L, Jankovic T, et al. Prevalence of oral herpes simplex virus reactivation in cancer patients: a comparison of different techniques of viral detection. J Oral Pathol Med. 2009;38:167–173
  41. Blijlevens N, Sonis S. Palifermin (recombinant keratinocyte growth factor-1): a pleiotropic growth factor with multiple biological activities in preventing chemotherapy- and radiotherapy-induced mucositis. Ann Oncol. 2007;18:817–826
  42. Tran CD, Sundar S, Howarth GS. Dietary zinc supplementation and methotrexate-induced small intestinal mucositis in metallothionein-knockout and wild-type mice. Cancer Biol Ther 2009;8, in press.
  43. Bushel PC, Forgery A, Grape FB, et al. Granulocyte macrophage colony-stimulating factor: current practive and novel approaches. Clin J Oncol Nurs. 2002;6:198–205
  44. Aspinall RJ, Pockros PJ. SCV-07. Curr Opin Invest Drugs. 2006;7:180–185
  45. Hunter A, Mahendra P, Wilson K, et al. Treatment of oral mucositis after peripheral blood SCT with ATL-104 mouthwash: results from a randomized, double-blind, placebo-controlled trial. Bone Marrow Transplant. 2009;43:563–569
  46. Porozov S, Cahalon L, Weiser M, et al. Inhibition of IL-1beta and TNF-alpha secretion from resting and activated human immunocytes by the homeopathic medication Traumeel S. Clin Dev Immunol. 2004;11:143–149

PII: S1368-8375(09)00892-6

doi: 10.1016/j.oraloncology.2009.08.006

Oral Oncology
Volume 45, Issue 12 , Pages 1015-1020 , December 2009

Article Tools

* Image Usage & Resolution